Structure/function notification burden queried
This article was originally published in The Tan Sheet
Executive Summary
FDA asks for dietary supplement firms' comments on the reporting burden of notifying the agency about structure/function claims. In a June 2 Federal Register 1notice, the agency estimates, based on submissions received in the past two years, that 2,200 firms will make the reports per year and each will require 0.75 hours to report the necessary information, for a total annual industry burden of 1,650 hours. The Dietary Supplement Health and Education Act requires manufacturers making structure/function claims on supplements to notify FDA of the claims within 30 days of a product reaching the market. The deadline for comments is Aug. 3, according to the notice
You may also be interested in...
Law firm asks for structure/function petition decision
The dietary supplement industry would have no reporting burden for structure/function claim notifications if FDA affirmed a citizen petition to revoke the claim notification rule, A. Wes Siegner says. The Hyman, Phelps & McNamara attorney reminded FDA in a Nov. 23 1letter that the agency has not responded to HPM's Feb. 4, 2000, petition, which asked FDA to rescind its disclaimer requirement for structure/function claims and its requirement that supplement firms notify FDA of such claims, as long as the claims are "truthful, non-misleading and derive[d] from nutritive value." Siegner's letter responds to FDA's June 2 Federal Register notice seeking comment on the burden of claim notification - estimated at 1,650 total hours annually (2"The Tan Sheet" June 8, 2009)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.